|| carrier of a CYP2C19*4 allele, considered a "slow metabolizer" variant
|| poor metabolizer
|?|| (A;A) (A;G) (G;G) ||28|
is a SNP in the CYP2C19
gene, potentially encoding the CYP2C19*4 variant. This variant has been linked to poor metabolism of compounds like mephenytoin. It is also known as M1V or Met1Val.[PMID 9435198
The risk allele is rs28399504(G).
As a nonfunctioning CYP2C19, this variant would be expected to be a poor metabolizer of several commonly prescribed drugs, including anti-ulcer drugs like omeprazole (trade names Losec and Prilosec), esomeprazole (trade name Nexium), and lansoprazole (Prevacid).
According to a 23andMe discussion This is one of the SNPs which were re-analyzed April 2009. Customers with older data may wish to redownload. SNPs effected rs4420638, rs34276300, rs3091244, rs34601266, rs2033003, rs7900194, rs9332239, rs28371685, rs1229984, and rs28399504.
] CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population
[PMID 18547414] Genotyping panel for assessing response to cancer chemotherapy.
|| Insufficiently evaluated pathogenic
|| This variant creates the CYP2C19*4 haplotype which is associated with poor metabolism of mephenytoin.
[PMID 23130019] Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.